[
    {
        "other_ids": [
            {
                "name": "Study Protocol Other Identifier",
                "value": "2016-002789-30"
            }
        ],
        "amendment_date": null,
        "keywords": null,
        "dcp_id": null,
        "interventional_model": "Parallel",
        "lead_org": "Regeneron Pharmaceuticals, Inc.",
        "eligibility": {
            "unstructured": [
                {
                    "inclusion_indicator": true,
                    "display_order": 0,
                    "description": "Dose escalation cohorts: Patients with histologically or cytologically confirmed diagnosis of malignancy (including lymphoma) with demonstrated progression of a tumor for whom there is no available therapy likely to convey clinical benefit AND who have not been previously treated with a PD-1/PD-L1 inhibitor. These patients do not require measurable disease"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 1,
                    "description": "Dose expansion cohorts: Patients with histologically or cytologically confirmed diagnosis of 1 of specified tumors with measurable disease per RECIST 1.1 or Lugano criteria. Some patients may have been previously treated with a PD-1 or PD-L1 inhibitor"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 2,
                    "description": "Eastern Cooperative Oncology Group performance status of 0 or 1"
                },
                {
                    "inclusion_indicator": true,
                    "display_order": 3,
                    "description": "Adequate organ and bone marrow function"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 4,
                    "description": "Prior treatment with any LAG-3 targeting biologic or small molecule"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 5,
                    "description": "Radiation therapy within 2 weeks prior to randomization and not recovered to baseline from any AE due to radiation"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 6,
                    "description": "Untreated or active central nervous system metastases - Ongoing or recent (within 5 years) evidence of significant autoimmune disease"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 7,
                    "description": "Corticosteroid therapy (>10 mg prednisone/day or equivalent) within 1 week prior to the first dose of study drug"
                },
                {
                    "inclusion_indicator": false,
                    "display_order": 8,
                    "description": "Myocardial infarction within 6 months"
                }
            ],
            "structured": {
                "max_age": "999 Years",
                "max_age_number": 999.0,
                "min_age_unit": "Years",
                "max_age_unit": "Years",
                "max_age_in_years": 999.0,
                "gender": "BOTH",
                "accepts_healthy_volunteers": false,
                "min_age": "18 Years",
                "min_age_number": 18.0,
                "min_age_in_years": 18.0
            }
        },
        "completion_date_type_code": "ANTICIPATED",
        "detail_description": null,
        "official_title": "A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies",
        "_phase_sort_order": 4,
        "collaborators": [
            {
                "name": "Sanofi Aventis",
                "functional_role": "LABORATORY"
            }
        ],
        "associated_studies": [],
        "outcome_measures": [
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Area under the curve (AUC) computed from time zero to the time of the last concentration [AUCall] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "AUCall-to-dose ratio [AUCall/Dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "AUC computed from time zero to the time of the last positive concentration [AUClast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "AUC from time zero extrapolated to infinity [AUCinf] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "AUCinf-to-dose ratio [AUCinf/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "AUClast-to-dose ratio [AUClast/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Best overall response based on irRECIST criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Best overall response based on Lugano criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Best overall response based on RECIST 1.1 criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Clearance [CL] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Cmax-to-dose ratio [Cmax/dose] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Disease control rate based on irRECIST criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Disease control rate based on Lugano criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Disease control rate based on RECIST criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to week 51",
                "name": "Duration of response based on irRECIST criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to week 51",
                "name": "Duration of response based on Lugano criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to week 51",
                "name": "Duration of response based on RECIST criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Incidence of adverse events (Dose Expansion Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Incidence of anti-drug antibodies (Dose Escalation Phase and Dose Expansion Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "From Baseline to the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 42 months",
                "name": "Incidence of death (Dose Expansion Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Incidence of serious adverse events (Dose Expansion Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Last positive (quantifiable) concentration [Clast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to week 51",
                "name": "Maximum Plasma Concentration [Cmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Mean residence time extrapolated to infinity [MRTinf] (Dose Escalation Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Mean residence time when the drug concentration profile is based on values up to and including the last positive concentration [MRTlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Escalation Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Number of patients with laboratory abnormalities (grade 3 or higher per Common Terminology Criteria for Adverse Events [CTCAE]) (Dose Expansion Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Objective response rate based on RECIST 1.1 for Solid Tumors (Dose Expansion phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Objective response rate by Lugano criteria for Lymphoma (Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to week 51",
                "name": "Objective response rate per Lugano criteria (lymphomas) (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to week 51",
                "name": "Objective response rate per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 (solid tumors) (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Observed terminal half-life [t1/2] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Occurrence of death (Dose Escalation Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Progression free survival based on irRECIST (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Progression free survival based on Lugano criteria (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Progression free survival based on RECIST (Dose Escalation Phase)",
                "description": null,
                "type_code": "SECONDARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Rate of adverse events (Dose Escalation Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 28 days",
                "name": "Rate of dose limiting toxicities (Dose Escalation Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Rate of serious adverse events (Dose Escalation Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "t1/2 beta (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Time of the last positive (quantifiable) concentration [tlast] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Time to Cmax [tmax] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Volume of distribution at steady state [Vss] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            },
            {
                "timeframe": "Baseline to 51 weeks",
                "name": "Volume of distribution of the terminal phase [Vz] (Primary: Dose Escalation Phase; Secondary: Dose Expansion Phase)",
                "description": null,
                "type_code": "PRIMARY"
            }
        ],
        "phase": "I",
        "central_contact": {
            "phone": null,
            "name": null,
            "type": null,
            "email": null
        },
        "primary_purpose": "TREATMENT",
        "number_of_arms": 2,
        "_study_protocol_type_sort_order": 0,
        "nct_id": "NCT03005782",
        "biomarkers": [],
        "classification_code": null,
        "current_trial_status_date": "2016-11-07",
        "diseases": [
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": false,
                "synonyms": [
                    "Lymphoma, NOS",
                    "Lymphomatous",
                    "Malignant Lymphoma",
                    "Lymphoma (Hodgkin and Non-Hodgkin)",
                    "Lymphoma (Hodgkin's and Non-Hodgkin's)",
                    "LYMPHOMA, MALIGNANT"
                ],
                "nci_thesaurus_concept_id": "C3208",
                "name": "Lymphoma",
                "type": [
                    "maintype",
                    "subtype"
                ],
                "parents": [
                    "C7065",
                    "C9305"
                ]
            },
            {
                "inclusion_indicator": "TRIAL",
                "is_lead_disease": true,
                "synonyms": [
                    "Advanced Cancer"
                ],
                "nci_thesaurus_concept_id": "C9270",
                "name": "Advanced Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C36263"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, secondary",
                    "Secondary Tumor",
                    "Tumor, secondary"
                ],
                "nci_thesaurus_concept_id": "C36255",
                "name": "Secondary Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "disease term",
                    "Disease",
                    "Diseases and Disorders",
                    "disease type",
                    "Disease or Disorder",
                    "Diagnosis",
                    "disease_term",
                    "condition",
                    "disease_type",
                    "Diseases",
                    "Disease or Disorder, Non-Neoplastic",
                    "Disorders",
                    "Disorder"
                ],
                "nci_thesaurus_concept_id": "C2991",
                "name": "Other Disease",
                "type": [
                    "maintype"
                ],
                "parents": []
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C7062",
                "name": "Neoplasm by Special Category",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasms, NOS",
                    "Neoplasia",
                    "Tumor, NOS",
                    "Neoplastic Growth",
                    "Neoplasm",
                    "Neoplastic Disease",
                    "tumor",
                    "Neoplasm, NOS"
                ],
                "nci_thesaurus_concept_id": "C3262",
                "name": "Other Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Neoplasm, malignant",
                    "Cancer",
                    "Malignant Growth",
                    "Tumor, malignant, NOS",
                    "Malignant Tumor",
                    "Malignancy",
                    "CA",
                    "Unclassified tumor, malignant",
                    "Malignant Neoplastic Disease"
                ],
                "nci_thesaurus_concept_id": "C9305",
                "name": "Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Cancer"
                ],
                "nci_thesaurus_concept_id": "C36263",
                "name": "Metastatic Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C4968",
                    "C3261"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Metastatic Tumor",
                    "Tumor, metastatic",
                    "Neoplasm, metastatic"
                ],
                "nci_thesaurus_concept_id": "C3261",
                "name": "Metastatic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C7062"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": true,
                "synonyms": [
                    "Secondary Malignancy",
                    "Secondary Cancer"
                ],
                "nci_thesaurus_concept_id": "C4968",
                "name": "Secondary Malignant Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9305",
                    "C36255"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Tumor Morphology",
                    "Tumor_Morphology"
                ],
                "nci_thesaurus_concept_id": "C4741",
                "name": "Neoplasm by Morphology",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Lymphoproliferative disease, NOS",
                    "Lymphoproliferative disorder, NOS"
                ],
                "nci_thesaurus_concept_id": "C9308",
                "name": "Lymphoproliferative Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C26323"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Hematopoietic and Lymphoid System Disease"
                ],
                "nci_thesaurus_concept_id": "C35814",
                "name": "Hematopoietic and Lymphoid System Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C27551"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Lymphoid Neoplasm",
                    "Lymphoid and Plasma Cell Tumor",
                    "Lymphocytic and Plasma Cell Neoplasm",
                    "Lymphoid and Plasmacytic Tumour",
                    "Lymphoid and Plasma Cell Tumour",
                    "Lymphoid and Plasmacytic Tumor",
                    "Lymphoid and Plasmacytic Neoplasm",
                    "Lymphocytic Tumor",
                    "Lymphocytic and Plasmacytic Neoplasm",
                    "Lymphoid Tumor",
                    "Lymphocytic and Plasma Cell Tumor",
                    "Lymphocytic and Plasma Cell Tumour"
                ],
                "nci_thesaurus_concept_id": "C7065",
                "name": "Lymphocytic Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C9308",
                    "C27134"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Malignant Hematopoietic Neoplasm",
                    "Hematopoietic Neoplasms Including Lymphomas",
                    "HEMOLYMPHORETICULAR TUMOR, MALIGNANT",
                    "Hematopoietic Cancer",
                    "Hematopoietic and Lymphoid Neoplasm",
                    "Hematologic Cancer",
                    "Hematologic Malignancy",
                    "Hematologic Neoplasm",
                    "Malignant Hematologic Neoplasm",
                    "Hematological Neoplasm",
                    "Hematopoietic malignancy, NOS",
                    "Hematopoietic Neoplasm"
                ],
                "nci_thesaurus_concept_id": "C27134",
                "name": "Hematopoietic and Lymphoid Cell Neoplasm",
                "type": [
                    "maintype"
                ],
                "parents": [
                    "C26323",
                    "C35813",
                    "C4741"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Hematopoietic and Lymphoid System Tumor"
                ],
                "nci_thesaurus_concept_id": "C35813",
                "name": "Hematopoietic and Lymphoid System Neoplasm",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3263",
                    "C35814"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Disease by Site"
                ],
                "nci_thesaurus_concept_id": "C27551",
                "name": "Disorder by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C2991"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [],
                "nci_thesaurus_concept_id": "C3263",
                "name": "Neoplasm by Site",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C3262"
                ]
            },
            {
                "inclusion_indicator": "TREE",
                "is_lead_disease": false,
                "synonyms": [
                    "Blood Disease",
                    "Blood Disorder",
                    "Hematological Disorder",
                    "Hematologic Disorder"
                ],
                "nci_thesaurus_concept_id": "C26323",
                "name": "Hematologic and Lymphocytic Disorder",
                "type": [
                    "subtype"
                ],
                "parents": [
                    "C35814"
                ]
            }
        ],
        "_primary_purpose_sort_order": 0,
        "protocol_id": "R3767-ONC-1613",
        "active_sites_count": 12,
        "lead_org_cancer_center": null,
        "arms": [
            {
                "interventions": [
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C143250",
                        "name": "Immune Checkpoint Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C141144"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Immune Mediators",
                            "Immunomodulatory Agent",
                            "Immunomodulating Agent",
                            "Biological Response Modifier",
                            "BRM",
                            "Immunopotentiators",
                            "Biomodulators",
                            "Immunomodulators",
                            "Immune Regulators",
                            "Immunotherapy Agent",
                            "Immunotherapeutic Agent",
                            "Immune Modulators"
                        ],
                        "nci_thesaurus_concept_id": "C308",
                        "name": "Immunotherapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Ab",
                            "Anticancer Antibody",
                            "Anti-cancer Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C129822",
                        "name": "Antineoplastic Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C129821"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Monoclonal Antibodies",
                            "Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C20401",
                        "name": "Monoclonal Antibody Therapy",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C307",
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-tumor Targeted Therapy Agent",
                            "Targeted Therapeutic Agent",
                            "Molecularly Targeted Therapy Agent",
                            "Targeted Agent"
                        ],
                        "nci_thesaurus_concept_id": "C163758",
                        "name": "Targeted Therapy Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-Tumor Agents",
                            "Antiproliferative Drugs",
                            "Cancer Drug",
                            "Chemotherapeutic Agents, Neoplastic Disease",
                            "Antiproliferative Agents",
                            "Tumor-Specific Treatment Agents",
                            "Antineoplastics",
                            "Anti-Tumor Drugs",
                            "Anti-Cancer Agents",
                            "Antineoplastic Drugs"
                        ],
                        "nci_thesaurus_concept_id": "C274",
                        "name": "Antineoplastic Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C132339",
                        "name": "Fianlimab",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C134305"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Drug",
                            "Pharmacologic Agent",
                            "Pharmaceuticals",
                            "Pharmaceutical Agent",
                            "Agent",
                            "Drug Substance",
                            "Pharmacological Substance"
                        ],
                        "nci_thesaurus_concept_id": "C1909",
                        "name": "Pharmacologic Substance",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1908"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C141144",
                        "name": "Immune Checkpoint Modulator",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C308"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Biopharmaceuticals",
                            "Immunologic, Immunochemical",
                            "Biologicals",
                            "Immunologics",
                            "Biologics",
                            "Biological Products"
                        ],
                        "nci_thesaurus_concept_id": "C307",
                        "name": "Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C1909"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [],
                        "nci_thesaurus_concept_id": "C1908",
                        "name": "Drug, Food, Chemical or Biomedical Material",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": []
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Antineoplastic Biological",
                            "Antineoplastic Biotherapeutic",
                            "Anticancer Biological",
                            "Anti-cancer Biological Agent"
                        ],
                        "nci_thesaurus_concept_id": "C129821",
                        "name": "Antineoplastic Biological Agent",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C274",
                            "C307"
                        ]
                    },
                    {
                        "inclusion_indicator": "TRIAL",
                        "synonyms": [
                            "Libtayo"
                        ],
                        "nci_thesaurus_concept_id": "C121540",
                        "name": "Cemiplimab",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent",
                        "parents": [
                            "C128037",
                            "C129822"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-PD-1 Monoclonal Antibody"
                        ],
                        "nci_thesaurus_concept_id": "C128037",
                        "name": "Anti-PD1 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C124946",
                            "C20401"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "PD-1 Inhibitor",
                            "Protein PD-1 Inhibitor",
                            "Programmed Cell Death Protein 1 Inhibitor",
                            "PD-1-targeting Agent"
                        ],
                        "nci_thesaurus_concept_id": "C124946",
                        "name": "PD1 Inhibitor",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C163758",
                            "C143250"
                        ]
                    },
                    {
                        "inclusion_indicator": "TREE",
                        "synonyms": [
                            "Anti-LAG3 Monoclonal Antibody",
                            "Anti LAG-3 MoAb"
                        ],
                        "nci_thesaurus_concept_id": "C134305",
                        "name": "Anti-LAG-3 Monoclonal Antibody",
                        "description": null,
                        "type": "Biological/Vaccine",
                        "category": "agent category",
                        "parents": [
                            "C143250",
                            "C20401",
                            "C129822"
                        ]
                    }
                ],
                "name": "Arm not specified",
                "description": null,
                "type": null
            },
            {
                "interventions": [],
                "name": "Combination Therapy (REGN3767+cemiplimab)",
                "description": "Group B will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition, 9 tumor-specific cohorts will be treated at the RP2D during dose expansion",
                "type": "EXPERIMENTAL"
            },
            {
                "interventions": [],
                "name": "Monotherapy (REGN3767)",
                "description": "Group A will consist of up to 4 sequential dose cohorts. Each cohort will receive 1 of 3 ascending dose levels of study drug during dose escalation. In addition 1 tumor-specific cohort will be treated at the recommended phase 2 dose (RP2D) during dose expansion.",
                "type": "EXPERIMENTAL"
            }
        ],
        "study_model_code": null,
        "nci_id": "NCI-2017-00409",
        "why_study_stopped": null,
        "brief_summary": "The primary objectives in the dose escalation phase are to evaluate safety and\r\n      pharmacokinetics (PK) in order to determine the selected dose level(s) for expansion of\r\n      REGN3767 as monotherapy and in combination with cemiplimab in patients with advanced\r\n      malignancies, including lymphoma.\r\n\r\n      The primary objectives in the dose expansion phase are to assess preliminary anti-tumor\r\n      activity of REGN3767 alone and in combination with cemiplimab (separately by cohort) as\r\n      measured by objective response rate (ORR).",
        "brief_title": "Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers",
        "status_history": [
            {
                "status_date": "2016-11-07T00:00:00",
                "status": "ACTIVE"
            }
        ],
        "study_population_description": null,
        "sampling_method_code": null,
        "minimum_target_accrual_number": 669,
        "_current_trial_status_sort_order": 0,
        "start_date": "2016-11-07",
        "record_verification_date": "2021-07-01",
        "ctep_id": null,
        "current_trial_status": "Active",
        "study_model_other_text": null,
        "masking": {
            "role_caregiver": null,
            "masking": null,
            "role_investigator": null,
            "role_outcome_assessor": null,
            "role_subject": null,
            "allocation_code": "Non-Randomized Trial"
        },
        "acronym": null,
        "nci_funded": "Indirect",
        "anatomic_sites": [
            "Multiple"
        ],
        "ccr_id": null,
        "start_date_type_code": "ACTUAL",
        "principal_investigator": null,
        "study_source": "Industrial",
        "completion_date": "2024-01-01",
        "study_subtype_code": null,
        "study_protocol_type": "Interventional"
    }
]